Patent Grant for Novel Anti-viral Seaweed Extract
Byotrol Plc
("Byotrol" or the "Company")
Patent Granted for Novel Anti-viral Seaweed Extract
Byotrol Plc (AIM: BYOT), the specialist infection prevention and control company, is pleased to report the approval today of a UK patent following its discovery of unique anti-viral properties of certain enhanced extracts of commonly available brown seaweed.
The award is a result of many years of research by Byotrol's technical team at its laboratories at Thornton Science Park, a University of Chester campus, and has been supported by the research scientists at the University of Liverpool led by Professor James Stewart, and by funding received from the Biotechnology and Biological Sciences Research Council (BBSRC) and Innovate UK.
The grant of the patent application gives Byotrol validated, valuable and protected intellectual property, to support the development of commercial relationships.
In the UK and Europe, seaweed extracts are not as yet approved as active materials for biocidal products, Byotrol's established area of expertise. So, we are now actively exploring alternative applications in very sizeable markets such as over-the-counter (OTC) products for the prophylactic treatment of viral conditions including colds, flu, coronaviruses and cold sores.
Byotrol Plc's Chairman, Dr Trevor Francis, comments:
"We are delighted to have secured the first patent for our seaweed-based anti-viral technologies. It is another good indication of the quality of our technical capability, and it will most certainly help us as we intensify the search for commercial partners. It also adds to our already significant level of intellectual property in antimicrobials.
"This patent further confirms Byotrol's commitment to developing and commercializing natural and sustainable antimicrobial actives."
For further information contact:
|
Byotrol Plc |
|
|
Dr Trevor Francis, Non- Executive Chairman |
+44 (0)1925 742 000 |
|
Vivan Pinto, Chief Executive Officer Chris Sedwell, Chief Financial Officer
|
|
|
|
|
|
finnCap Limited (Nominated Adviser and Broker) |
+44 (0)20 7220 0500 |
|
Geoff Nash/George Dollemore - Corporate Finance Nigel Birks/Harriet Ward - ECM |
|
|
|
|
|
|
|
|
Flagstaff Strategic and Investor Communications |
+44 (0)20 7129 1474 |
|
Tim Thompson/Andrea Seymour/Fergus Mellon |
|
This announcement is released by Byotrol Plc and, prior to publication, the information contained herein was deemed to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014. Such information is disclosed in accordance with the Company's obligations under Article 17 of MAR.
Notes to editors
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.
Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.
Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.
For more information, go to byotrol.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 2 minutes ago Aurrigo International
- 26 minutes ago Savills
- 46 minutes ago Everyman Media Group
- 1 hour ago Croda International
- 2 hours ago Diageo